Aggregator

HHS memo says Ralph Baric had a “pattern of deception” in describing virus studies long before pandemic

Growing awareness of “copathology” inspires new diagnostic tests and clinical trials

The U.S. government has recently convicted multiple postdocs for improper shipments of biological materials. Some see a replay of the 2018 China Initiative

Pending appointments of Laura Delano and David Cohen raise concerns that key advisory groups are becoming politicized

Staying strong may be one of the biggest secrets to living longer — especially for older women. A major study of more than 5,000 women found that simple signs of muscle strength, like a firm hand grip or the ability to quickly stand up from a chair, were strongly linked to lower risk of death over the next eight years.

Researchers say fructose is not just “empty calories” — it may actively push the body toward fat storage and metabolic disease. A new review found that fructose affects the body differently from glucose, disrupting normal energy regulation and promoting processes linked to obesity, insulin resistance, and cardiovascular problems.

Memory decline, particularly in neurodegenerative disorders such as Alzheimer's disease, represents a critical global public health challenge, with projections exceeding 150 million cases by 2050. Current therapeutic options remain limited: while drugs like donepezil and memantine offer symptomatic relief, and newer agents like lecanemab show modest effects on slowing progression, no disease-modifying cures exist. This underscores the urgent need to refine preclinical models bridging discovery...

Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ), with soluble oligomers widely recognized as key drivers of neurotoxicity through disruption of synaptic function, mitochondrial integrity, and cellular homeostasis. Targeting Aβ aggregation therefore represents a compelling therapeutic strategy. Here we report a synthetic peptidomimetic foldamer, M4, as a potent modulator of Aβ42 aggregation. Biophysical analyses demonstrate that M4 binds Aβ with high affinity,...

Memory decline, particularly in neurodegenerative disorders such as Alzheimer's disease, represents a critical global public health challenge, with projections exceeding 150 million cases by 2050. Current therapeutic options remain limited: while drugs like donepezil and memantine offer symptomatic relief, and newer agents like lecanemab show modest effects on slowing progression, no disease-modifying cures exist. This underscores the urgent need to refine preclinical models bridging discovery...